ClinicalTrials.gg
RecruitingNCT07520201Updated Jun 30, 2026

Comparison Between 3 Conservative Surgeries for Placenta Accreta Spectrum

An interventional study of Modified one-step surgery and Segment Resection in Placenta Accreta Spectrum, sponsored by Assiut University. Recruiting at 1 site in Egypt. Open to female participants. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Sex
Female
01

Study summary

Comparison between modified one-step surgery vs. Segment Resection vs. placental bed suturing for management of placenta accreta spectrum

Read the detailed description

Placenta accreta spectrum (PAS) represents a severe obstetric disorder, defined by abnormal migration of the placenta into the myometrium, which leads to incomplete or absent placental separation following delivery. Peripartum caesarean hysterectomy remains the most widely used treatment and is regarded as the gold standard in the majority of clinical settings. Recent international and national guidelines recognize uterus-preserving surgery, including focal resection, as a valid management option in centres of excellence for selected women. However, long-term data on physical outcomes following these procedures remain limited. This study aimed to evaluate intraoperative and postoperative outcomes of patients with placenta accreta spectrum treated with modified one-step conservative surgery, Myometrial segment Resection or placental bed suturing.

02

Conditions studied

  • Placenta Accreta Spectrum

Browse trials for

Keywords

  • Segment Resection
  • Modified one-step
  • Placental bed plication
  • Conservative uterine surgery
03

In context

Placenta Accreta

150 studies on the registry are indexed under Placenta Accreta; 40 are open to participants now.

This study's planned enrollment of 42 is below the median of 70 across 67 interventional studies indexed under Placenta Accreta.

Browse Placenta Accreta studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pregnant women with placenta accreta spectrum

Exclusion criteria

Exclusion Criteria:

  • Patients refuse to share in the study
  • Pregnant \< 28 weeks
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
Double (Investigator, Outcomes assessor)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Modified one-step surgery

    Procedure: Modified one-step surgery

  • Experimental
    Segment Resection

    Procedure: Segment Resection

  • Experimental
    Placental bed suturing

    Procedure: Placental bed suturing

Interventions

  • ProcedureModified one-step surgery

    transverse uterine incision is made at the upper border of the placenta without cutting through the placenta, then fetal delivery. A tourniquet is first put into the para-cervical area (using a Foley 12-F catheter) to stop active bleeding, and bilateral uterine artery ligation (using Chromic 1/0) is performed, followed by manual placental removal . Myometrial resection is performed if the remaining lower uterine segment of the healthy myometrium measures more than 2 cm. Suture of both edges of the uterine incision and hemostatic sutures of the placental bed surface (using chromic suture 1/0) are performed. Finally, the tourniquet is released and a transverse B-Lynch compression suture is made

  • ProcedureSegment Resection

    transverse uterine incision was applied just above the upper border of involved uterine wall . And the fetus was extracted from this incision and the umbilical cord was clamped. In order to decrease hemorrhage, anterior branches of hypogastric arteries were ligated bilaterally. urinary bladder dissection from anterior uterine wall is done. Then the involved segment is resected by leaving placental free tissue medially to the uterine arteries, below transverse uterine incision and above the cervix. Resection was made by scissors or cautery and bleeding from the borders was controlled by ring forceps.

  • ProcedurePlacental bed suturing

    After the separation of the placenta, all bleeding areas are clamped with several curved ovarian forceps. After the mechanical hemostasis of the lower uterine segment has been achieved, the remaining small amounts of placental fragments are removed by instrument. The clamps are removed sequentially, and the vesicouterine interface and all spaces are sutured with superficial stitches under the guidance of the surgeon's fingers. These superficial continuous sutures are not very deep. Cho sutures are used to achieve comlete hemostasis.

06

What researchers measure

Primary outcomes

  1. Intraoperative Blood loss

    Increased blood loss means bad outcome

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07520201
Lead sponsor
Assiut University
Responsible party
Mohamed Gamal M.fekry (Lecturer obstetric and gynecology, Specialist Urogynecology, Assiut University) — Principal investigator
First posted
Apr 9, 2026
Start date
Jun 26, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jun 30, 2026

Study contacts

Mohammed Gamal, PhD
Contact
mohamedbeethoven2040@gmail.com
+20882312388

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion